PFIZER INC.

Researchers found a drug, ponsegromab, effectively treats cachexia in cancer patients by blocking the GDF-15 hormone, improving symptoms with minimal side effects, as reported in a phase 2 clinical trial in the New England Journal of Medicine.

Roche's Xofluza reduced flu transmission in households in a Phase 3 study, marking the first time an antiviral has shown such efficacy in a global trial. The study involved over 4,000 participants aged 5-64, with no new safety concerns identified. Full data will be presented at an upcoming medical meeting.

The 'Crohn's Disease - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights on 70+ companies and 80+ pipeline drugs, including clinical and nonclinical stage products, therapeutic assessments, and emerging drugs like Ozanimod, Etrasimod, CBP-307, and IMU-856. The report highlights the current scenario and growth prospects in Crohn's Disease treatment, focusing on novel approaches and key players in the field.

Pharmaceutical industry inefficiencies stem from high costs per drug approval, frequent C-level executive changes, and strategic R&D restructuring unrelated to science. AI-drug discovery companies should commit to programs until Phase I completion to avoid waste and maximize patient benefit.

Organon plans to acquire Dermavant for up to $1.2 billion, gaining its commercialized plaque psoriasis drug Vtama, which is under FDA review for atopic dermatitis. Vtama sales grew to $75.1 million in FY2023, but face competition in a crowded market. Organon aims to leverage its global scale to expand Vtama's reach.

Novartis' Kisqali gains broad FDA approval for early HR+/HER2- breast cancer, reducing recurrence risk by 25% in NATALEE trial, surpassing Eli Lilly's Verzenio in node-negative cases. Kisqali's potential to reach $7 billion in sales is boosted by this approval.

Novartis' Kisqali gets FDA approval for early-stage breast cancer; GSK's vaccines for RSV and shingles co-administered effectively; Novo Nordisk partners with NanoVation for genetic therapies; AstraZeneca's Mene Pangalos joins Omega Funds; Serán Biosciences secures $200M for new facility; Boehringer Ingelheim's nerandomilast shows success in Phase 3 IPF trial.

Power's AI platform simplifies patient access to clinical trials, reducing recruitment delays and enhancing patient understanding, as highlighted at DPHARM Idol Disrupt 2024.

FDA approves Novartis' Kisqali for HR+/HER2- stage II and III early breast cancer, significantly expanding eligible patient population.

Bispecific antibodies, with two binding domains, offer targeted therapeutics and address co-administration challenges, gaining traction in biopharma. Initially approved for cancer, they now target various diseases, with 12 approved in the U.S. and more in development. Their dual action reduces patient burden and enhances treatment effects, potentially transforming therapeutic paradigms beyond oncology. The market is projected to grow significantly due to rising chronic disease incidence and technological advancements.